Recommendations of the Czech Society for Rheumatology for the treatment of gouty arthritis
Authors:
K. Pavelka
Authors place of work:
Revmatologický ústav a Klinika revmatologie 1. LF UK, Praha
Published in the journal:
Čes. Revmatol., 20, 2012, No. 2, p. 82-92.
Category:
Recommendation
Summary
In the introduction, the author stresses the need for accurate diagnosis of gout. You can use ACR criteria or newly published EULAR diagnostic criteria. In both criteria, there is an absolute diagnosis based on the proof of sodium urate crystals. The need for a crystallographic analysis of all effusions of unknown etiology is emphasized as well. Cessation of a gout attack as soon as possible, normalization of serum levels of uric acid and removal of urate deposits in the body are the principal objectives in the treatment of gout. Furthermore, the associated diseases need to be addressed and the complications of gout prevented. Early anti-inflammatory treatment is of high importance in the treatment of acute inflammation. Non-steroidal anti-inflammatory drugs (NSAIDs) are the drug of choice in uncomplicated gout. Colchicine is used in patients with unclear diagnosis or contraindication to NSAIDs. Even lower dosages of colchicine (0.5 mg 3 times daily) are momentarily recommended, because conventional dosage often leads to adverse effects. A third alternative in the treatment of acute inflammation is the administration of corticosteroids. In cases with mono- or oligoarthritis, intra-articular administration of long-acting corticosteroids is highly recommended. Exclusion of septic arthritis is required. Systemic administration of corticosteroids at an initial dose of 20-50 mg with tapering within two to three weeks is a possible alternative, and is sometimes used especially in forms with polyarticular gout or in cases, where NSAIDs and colchicine cannot be used. However, new attacks occur more frequently after tapering of the dose. Thus, corticosteroids are considered a second-line treatment of gout. During acute inflammation we do not affect hyperuricemia. We initiate the reduction of uricaemia after resolution of acute attacks. Chronic tophaceous gout and radiographically progressive gout are another indication of the correction of hyperuricemia. Non-pharmacological and pharmacological treatment can be used in reducing uricaemia. Non-pharmacological methods should be applied for each patient and should include weight reduction, low-purine diet and alcohol abstinence. Uricosuric and uricostatic agents can be used for pharmacological reduction of uricaemia. Uricosuric agents are indicated only in patients without renal disease (lithiasis). Currently, there is no uricosuric agent available on the Czech market. The most used drug for the treatment of hyperuricaemia is the xanthine oxidase inhibitor allopurinol. It is administered at doses of 100-900 mg per day and an individual dose for each patient must be titered. In case of intolerance or lack of efficacy of allopurinol, a non-purine selective inhibitor of xanthine oxidase, febuxostat, is now available as a second-line treatment of hyperuricaemia. The recommended dose of febuxostat is 80 mg daily. Initiation of an effective hypouricaemic treatment can trigger new attacks, therefore a colchicine prophylaxis for 3-6 months is recommended. For patients with gout often have gout-associated diseases (hypertension, dyslipidemia, diabetes, metabolic syndrome), these should be monitored and treated in collaboration with a relevant specialist. Pegylated uricase (pegloticase) and monoclonal antibody against IL-1 (canakinumab) are promising new drugs for refractory gout that are currently in the final phase of testing and approval.
Key words:
gouty arthritis, therapy
Zdroje
1. Lawrence RC, Helmick CG, Arnett FC et al: Estimates of the prevalence of arthritis and selected musculosceletal disorders in the United States. Arthritis Rheum 1998;4(1):778-99.
2. Mikuls TR, Farrar JT, Bilker WB, et al: Gout epidemiology: results from the UK General Practise Research Database 1990-1999. Ann Rheum Dis 2005;64:267-72.
3. Wallace SL, Robinson H, Masi AT, et al: Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977;20:895-900.
4. Zhang W, Doherty M, Pascual E, et al: EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of task force of the standing committee for international clinical studies including therapeutics. Ann Rheum Dis 2006;65:1301-1311.
5. Wise C: Crystal associated arthritis in the elderly. Rheum Dis Clin N Am 2007;33:33-75
6. Reyes A. Cardiovascular drugs and serum uric acid. Cardiovasc Drugs Ther 2003;17:397-414.
7. Krishnan E, Baker J, Furst D, et al: Gout and the risk of acute myocardial infarction. Arthritis Rheum 2006;54: 2688-2696.
8. Wortmann RL. Recent advances in the management of gout and hyperuricemia. Curr Opin Rheumatol 2005;17: 319-324.
9. Ahern MJ, Reid C, Gordon C, et al: Does colchicine work? The results of first study in acute gout. Aust NZ J Med 1987;17:301-304.
10. Terkeltaub RA, Furst DE, Bennett K, et al. High Versus Low Dosing of Oral Colchicine for Early Acute Gout Flare. Arthritis Rheum 2010;4:1060-1068.
11. Rubin BR, Burton R, Novarra S, et al.: Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indometacin 50 mg three times daily in acute gout: a randomized ,controlled trial. Arthritis Rheum 2004;50:598-606.
12. Ofmann JJ, Mac Lean CH, Strauss WL, et al.: A metaanalysis of severe upper gastrointestinal complications of nonsteroidal antirehumatic drugs. J Rheumatol 2002;29: 169-182.
13. Hooper L, Brown TJ, Elliot R, et al: The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs? Systematic review. BMJ 2004;329:948-52.
14. Solomon SD, Mc Murray JIV, Pfeiffer MA, et al: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-80.
15. Fernandez C, Noguera R, Gonzales JA, et al: Treatment of acute atacts of gout with a small dose of triamcinolon acetonide. J Rheumatol 1999;26:2285-86.
16. Groff CD, Franck DA, Radtz DA: Systemic steroid therapy for acute gout: a clinical trial and review of the literature. Semin Arthritis Rheum 1990;19:329- 36.
17. Alloway JA, Moriarty MJ, Hoogland YT a spol: Comparison of triamcinolone acetonide with indomethacin in the treatment of acute gouty arthritis. J Rheumatol 1993; 20:111-113.
18. Lin KC, Lin HY, Chou P. Community based epidemiological study on hyperuricemia and gout in Kin Hu. J Rheumatol 2000;27:1045-1050.
19. Dessein PH, Shipton AE, Stanwix AE, et al: Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction and increased proportional intake of protein and unsaturated fat on serum and lipoprotein levels in gout a pilot study. Ann Rheum Dis 2000;59:539-43.
20. Choi E, Atkinson K, Karlson EW, et al.: Alcohol intake and risk of incident gout in men: a prospective study. Lancet 2000;363:1277-81.
21. Perez –Ruiz F, Liote F.: Lowering serum uric acid levels: What is the optimal target for improving clinical outcomes in gout. Arthritis Rheum 2007;57:1324-1328.
22. Perez- Ruiz F, Calabozo M, Pijaan JI, et al: Effect of urate lowering therapy on the velocity of size of reduction of tophi in chronic gout. 2002;47:355-60.
23. Hande KR, Noone RM, Stone WJ, et al.: Severe allopurinol toxicity descrition and guidelines for preventive in patients with renal insuficency. Am J Med 1984;76:47-56.
24. Jansen TL, Richette P, Oerez Ruiz F, et al.: International position paper on febuxostat. Clin Rheumatol 2010;29: 835-840.
25. Becker MA, Schumacher HR, Wortmann RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 298 week, phase III randomized trial. Arthritis Care Res 2008;59:1540-1548.
26. Schumacher HR, Becker MA, Lloyd E, et al: Febuxostat in the treatment of gout.5 year findings of the FOCUS efficacy and safety study. Rheumatology 2009;48:188-194.
27. Bomalski JS, Clarck M.: Serum uric acid-lowering therapies: where are we fading in management of hyperuricemia and potential role of uricase. Curr Rheum Rep 2004;6: 240-247.
28. Schlesinger N, Mysler E, Hsiao-Yi Lin, et al. Cinazinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. Ann Rheum Dis 2011;70:1264-1271.
Štítky
Dermatology & STDs Paediatric rheumatology RheumatologyČlánok vyšiel v časopise
Czech Rheumatology
2012 Číslo 2
Najčítanejšie v tomto čísle
- Raynaud’s phenomenon and peripheral ischemic syndromes
- Recommendations of the Czech Society for Rheumatology for the treatment of gouty arthritis
- Obesity, adipose tissue and cardiovascular risk in rheumatoid arthritis
- Ultrasound scoring systems: assessing disease activity in rheumatoid arthritis